Related Experiment Videos
Sclerodermatous graft-versus-host disease after donor leucocyte infusion
M Jones-Caballero1, J Fernández-Herrera, S Córdoba-Guijarro
1Ambulatorio Hermanos Sangro, Area 1 de Salud de Madrid, Spain. derma/princesa@hup.es
The British Journal of Dermatology
|January 20, 1999
Summary
Leukocyte infusion can help patients with relapsed leukemia by using donor immune cells to target cancer cells. However, this therapy may cause graft-versus-host disease, a serious complication.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Leukocyte infusion from a marrow donor is an emerging therapy for recurrent leukemia, aiming to prevent repeat bone marrow transplants.
- This treatment leverages the graft-versus-leukemia (GVL) effect, where donor immune cells identify and eradicate remaining leukemia cells.
Observation:
- A patient with relapsed chronic myeloid leukemia received donor leukocyte infusion after undergoing two bone marrow transplants.
- Following the infusion, the patient developed sclerodermatous graft-versus-host disease.
Findings:
- Donor leukocyte infusion can be effective in managing relapsed leukemia.
- The GVL phenomenon, while beneficial for leukemia control, can precipitate graft-versus-host disease (GVHD).
Implications:
- This case highlights the critical balance between harnessing the graft-versus-leukemia effect and managing the risk of graft-versus-host disease.
- Further research is needed to optimize donor leukocyte infusion protocols to maximize therapeutic benefits while minimizing GVHD complications.